Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: May 20, 2025
Event: Closing of a multi-tranche senior notes offering to fund a strategic acquisition.
Key Financial Metrics and Capital Structure
The Company issued three tranches of unsecured, unsubordinated senior notes with a total aggregate principal amount of $2.0 billion. The offering generated approximately $1,989.7 million in net proceeds after underwriting discounts but before estimated offering expenses.
| Note Series | Principal Amount | Coupon Rate | Maturity Date | Public Offering Price (% of Principal) |
|---|---|---|---|---|
| 2030 Notes | $650,000,000 | 4.650% | May 30, 2030 | 99.960% |
| 2032 Notes | $650,000,000 | 4.950% | May 30, 2032 | 99.930% |
| 2035 Notes | $700,000,000 | 5.250% | May 30, 2035 | 99.777% |
Interest Payments: Payable semi-annually on May 30 and November 30, commencing November 30, 2025.
Use of Proceeds: To fund the acquisition of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC, alongside cash on hand and/or commercial paper borrowings.
Material Changes and Debt Terms
- Redemption Rights: The Company may redeem notes prior to maturity at a "make-whole" premium based on the Treasury Rate plus a spread (10 basis points for 2030 Notes; 15 basis points for 2032 and 2035 Notes). Post-maturity dates, notes may be redeemed at par plus accrued interest.
- Change of Control: If a change of control occurs and the notes are downgraded below investment grade, the Company must offer to repurchase the notes at 101% of the principal amount plus accrued interest.
- Covenants: The Indenture includes limitations on creating liens, sale and leaseback transactions, and consolidations/mergers, subject to standard exceptions.
Outlook, Risks, and Management Commentary
The filing indicates a strategic expansion into the oncology services sector through the acquisition of Community Oncology Revitalization Enterprise Ventures, LLC. The capital structure now includes significant long-term debt obligations maturing between 2030 and 2035. The filing notes that the agreements contain representations and warranties that may not reflect the current state of affairs and are subject to materiality standards different from those of investors.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after all offering expenses.
- Confirm the specific terms of the acquisition of Community Oncology Revitalization Enterprise Ventures, LLC, including the total transaction value and funding mix.
- Review the full text of the Officer's Certificate (Exhibit 4.1) and Underwriting Agreement (Exhibit 99.1) for detailed covenant restrictions and make-whole calculation methodologies.
- Monitor the Company's credit rating to assess the risk of triggering the change of control repurchase provision.